Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Rationale and recruitment in the PARTNER trial

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.17
Views: 1563
Rating:

Dr Jean Abraham - University of Cambridge, Cambridge, UK

Dr Jean Abraham met with ecancer at SABCS 2017 to discuss the PARTNER trial establishing the safety of olaparib added to neoadjuvant platinum chemotherapy for women with triple negative and/or mBRCA breast cancer.

She outlines the trial design, eligibility, and patient recruitment so far.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation